|
| 37879077 | Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. | Blood | 2024 |
| 38086946 | Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. | Leukemia | 2024 |
| 38054837 | Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients. | Leuk Lymphoma | 2024 |
| 37646654 | Myeloid lineage switch in <i>KMT2A-</i>rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. | Haematologica | 2024 |
| 36322818 | Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. | Blood Adv | 2023 |
| 37635400 | Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. | Am J Hematol | 2023 |
| 37665752 | Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. | Am J Hematol | 2023 |
| 37486624 | Cigarette smoke exposure accelerates AML progression in FLT3-ITD models. | Blood Adv | 2023 |
| 37585491 | Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. | Clin Cancer Res | 2023 |
| 37550272 | Invasive mucorales sinusitis in a young patient with Emberger syndrome and newly diagnosed AML: A case report and literature review of invasive fungal infections in GATA2 deficiency. | Mycoses | 2023 |
| 37841255 | Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. | Front Immunol | 2023 |
| 37735426 | Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. | Blood Cancer J | 2023 |
| 37690903 | Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37608562 | Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. | Br J Haematol | 2023 |
| 37730483 | Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia. | Clin Lymphoma Myeloma Leuk | 2023 |
| 35353219 | A phase 1 study of IDH305 in patients with IDH1<sup>R132</sup>-mutant acute myeloid leukemia or myelodysplastic syndrome. | J Cancer Res Clin Oncol | 2023 |
| 35405739 | Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy. | Blood Adv | 2023 |
| 35714312 | Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. | Blood | 2023 |
| 37354069 | Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study. | Am J Hematol | 2023 |
| 36951163 | Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). | Haematologica | 2023 |
| 37422688 | A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. | J Hematol Oncol | 2023 |
| 37055414 | Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. | Blood Cancer J | 2023 |
| 37187201 | Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. | Lancet Haematol | 2023 |
| 37154083 | DDX41 mutations in patients with non-myeloid hematologic neoplasms. | Am J Hematol | 2023 |
| 37386016 | A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. | Blood Cancer J | 2023 |
| 37285177 | Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. | Cancer Immunol Res | 2023 |
| 37185307 | Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. | Leukemia | 2023 |
| 37046645 | Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience. | Cancers (Basel) | 2023 |
| 36977823 | Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. | Leukemia | 2023 |
| 37441846 | Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. | Blood | 2023 |
| 37406166 | Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. | Blood Adv | 2023 |
| 37104058 | Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. | Blood Adv | 2023 |
| 37102976 | A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies. | Blood Cancer Discov | 2023 |
| 37334870 | Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. | Am J Hematol | 2023 |
| 37068505 | Acute myeloid leukaemia. | Lancet | 2023 |
| 37196217 | Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in <i>ABL</i> Class Rearrangements. | JCO Precis Oncol | 2023 |
| 37163233 | Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. | Cancer Immunol Res | 2023 |
| 37462435 | <i>IDH2</i> mutations in acute myeloid leukemia. | Leuk Lymphoma | 2023 |
| 36884300 | Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. | Blood Adv | 2023 |
| 36477735 | Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia. | Cancer | 2023 |
| 36882573 | Association between bariatric surgery and outcomes in chronic myeloid leukemia. | Cancer | 2023 |
| 36715486 | Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. | Cancer | 2023 |
| 36683287 | The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. | Am J Hematol | 2023 |
| 36906610 | Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress. | Nat Commun | 2023 |
| 36900407 | Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance. | Cancers (Basel) | 2023 |
| 36865338 | Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. | Res Sq | 2023 |
| 36600670 | Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. | Am J Hematol | 2023 |
| 36458426 | A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. | Cancer | 2023 |
| 36762937 | Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets. | Expert Opin Investig Drugs | 2023 |
| 36565294 | Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. | Am J Hematol | 2023 |